Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy
BackgroundChimeric antigen receptor T cell infusion (CAR T) therapy has revolutionized the treatment of hematologic malignancies, but treatment-related toxicities are of concern. Understanding the timing and reasons for which patients present to the emergency department (ED) after CAR T therapy can...
Main Authors: | Demis N. Lipe, Aiham Qdaisat, Patrick Chaftari, Monica K. Wattana, Pavitra P. Krishnamani, Cielito Reyes-Gibby, Sai-Ching J. Yeung |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1122329/full |
Similar Items
-
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01) -
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
by: Stefan Stoiber, et al.
Published: (2019-05-01) -
Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors
by: Farhana Jahan, et al.
Published: (2023-02-01) -
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
by: Maria Giraudo, et al.
Published: (2024-03-01) -
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
by: Samer A. Srour, et al.
Published: (2023-01-01)